A Clinical Study of TQH2929 in Healthy Adult Subjects
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This project is divided into a single dose escalation and a multiple dose escalation phase Ia
clinical study. This is a single-center, randomized, double-blind, placebo-controlled study
to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929
injection in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.